Viromed Medical AG Announces Leadership Changes

Viromed Medical AG, a company recognized for its innovations in cold plasma technology, has announced plans for a leadership transition in its Supervisory Board. This change is scheduled to take effect following the Annual General Meeting on July 29, 2025. Dr. Thomas Gutschlag has been nominated for election to the Supervisory Board and is expected to assume the role of Chairman. The current Chairman, Dr. Jan Delphendahl, will resign at the end of the meeting.

Dr. Gutschlag, who also leads Deutsche Rohstoff AG, brings valuable financial market experience to the board. This transition is seen as a strategic move to support Viromed's ongoing growth and innovation efforts. Uwe Perbandt, CEO of Viromed, expressed confidence in Dr. Gutschlag's ability to guide the company through its expansion phase.

Additionally, Dr. Gutschlag has already made a significant investment in the company by purchasing 100,000 shares. Further share acquisitions are planned, signaling strong commitment to Viromed's future developments and success.